Analysts Are Recommending Lexicon Pharmaceuticals Inc (LXRX) As A Buy Candidate
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) has a beta value of 1.17 and has seen 3.26 million shares traded in the last trading session. The company, currently
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) has a beta value of 1.17 and has seen 3.26 million shares traded in the last trading session. The company, currently
During the last session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s traded shares were 7.67 million, with the beta value of the company hitting 1.17. At the end
In the last trading session, 1.65 million shares of the Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) were traded, and its beta was 1.17. Most recently the company’s
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s traded shares stood at 2.81 million during the last session, with the company’s beta value hitting 1.18. At the close of
In the latest trading session,, 1.52 million Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) shares changed hands as the company’s beta touched 1.07. With the company’s most recent
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) has a beta value of 1.03 and has seen 1.18 million shares traded in the recent trading session. The company, currently
In today’s recent session, 1.71 million shares of the Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) have been traded, and its beta is 1.01. Most recently the company’s
In the last trading session, 3.89 million Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) shares changed hands as the company’s beta touched 1.01. With the company’s per share
In last trading session, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) saw 3.76 million shares changing hands with its beta currently measuring 1.01. Company’s recent per share price
© 2024, Powered by Smart TechOne